Group 1 - The Zhongzheng Traditional Chinese Medicine Index (930641) increased by 0.32%, with notable gains from companies such as Guangdong Wannianqing (301111) up 12.03%, and Panlong Pharmaceutical (002864) up 5.35% [1] - The demand for new therapies such as peptides, ADCs, small nucleic acids, and CGT is expected to remain high, with a recovery in outsourcing demand anticipated due to the overseas interest rate cut cycle [1] - The adjustment of the basic drug catalog is expected to continue, presenting opportunities for the adjustment of traditional Chinese medicine varieties [1] Group 2 - The Zhongzheng Traditional Chinese Medicine Index includes companies involved in the production and sales of traditional Chinese medicine, reflecting the overall performance of the sector [2] - As of November 28, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.79% of the index, with notable companies including Yunnan Baiyao (000538) and Pianzaihuang (600436) [2]
中药ETF(159647)涨近1%，多地流感活动呈上升趋势
Xin Lang Cai Jing·2025-12-03 02:56